Area of research
Hepatology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include DNA damage, Cancer research, FOXM1, PI3K/AKT/mTOR pathway, NF-κB, and Nanotechnology.
2592MO Fruquintinib (FRUQ) plus sintilimab (SIN) versus axitinib (AXI) or everolimus (EVE) monotherapy as 2L treatment in pts with locally advanced or metastatic renal cell carcinoma (RCC): Results from phase III part of a randomized, open-label, active-controlled phase II/III study (FRUSICA-2)
High-resolution combinatorial patterning of functional nanoparticles
Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas